FDA's Initial IND Warnings For CBD Supplements Could Ignite Regulatory Test
This article was originally published in The Tan Sheet
FDA's warnings that supplements containing cannabis-derived ingredients are adulterated comes 10 months year after it stated the policy and a year after submitting other warnings that stopped short of saying the ingredients are noncompliant.
You may also be interested in...
UK advertising regulator says an ad catalog retailer claiming a CBD patch could reduce chronic pain, anxiety and diabetes violated advertising codes. The agency says claims including the product penetrated quickly through skin were medicinal and not approved by the UK or EU.
Two CBD marketers warned by FDA in a recent crackdown are targeted in class action complaints alleging they made unsubstantiated health claims and mislabeled ‘illegal drug’ products as supplements. Complaints are a wake-up call to CBD wellness industry to ensure claims are substantiated, as the class action bar is on the prowl following the agency’s 15 warning letter blast in November.
As FDA announces its first-ever approval of a drug that contains a substance derived from marijuana, officials say the agency's policy that prohibits CBD's use in dietary supplements or food will not change. They also say, however, that FDA's priority for enforcement actions against dietary supplements containing CBD, an extract from cannabis and hemp plants, will remain on products marketed with drug or disease claims.